机构:[1]College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China[2]Laboratory for Clinical Immunology, Harbin Children’s Hospital, Harbin, China[3]College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing, China[4]Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China神经科系统神经内科首都医科大学宣武医院[5]Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern (VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 vaccines mainly include inactivated, live attenuated, viral vector, protein subunit, RNA, DNA, and virus-like particle (VLP) vaccines. Viral vector vaccines, protein subunit vaccines, and mRNA vaccines may induce additional cellular or humoral immune regulations, including Th cell responses and germinal center responses, and form relevant memory cells, greatly improving their efficiency. However, some viral vector or mRNA vaccines may be associated with complications like thrombocytopenia and myocarditis, raising concerns about the safety of these COVID-19 vaccines. Here, we systemically assess the safety and efficacy of COVID-19 vaccines, including the possible complications and different effects on pregnant women, the elderly, people with immune diseases and acquired immunodeficiency syndrome (AIDS), transplant recipients, and cancer patients. Based on the current analysis, governments and relevant agencies are recommended to continue to advance the vaccine immunization process. Simultaneously, special attention should be paid to the health status of the vaccines, timely treatment of complications, vaccine development, and ensuring the lives and health of patients. In addition, available measures such as mix-and-match vaccination, developing new vaccines like nanoparticle vaccines, and optimizing immune adjuvant to improve vaccine safety and efficacy could be considered.
基金:
National Key Research and Development Program of China [2022YFC0867500, BWS21J025, 20SWAQK22, 2020YFA0712102]; National Natural Science Foundation of China [82151224]; Key Project of Beijing University of Chemical Technology [XK1803-06, XK2020-02]; Fundamental Research Funds for Central Universities [BUCTZY2022]; H&H Global Research and Technology Center [H2021028]
第一作者机构:[1]College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
通讯作者:
通讯机构:[1]College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China[5]Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China
推荐引用方式(GB/T 7714):
Li Maochen,Wang Han,Tian Lili,et al.COVID-19 vaccine development: milestones, lessons and prospects[J].SIGNAL TRANSDUCTION AND TARGETED THERAPY.2022,7(1):doi:10.1038/s41392-022-00996-y.
APA:
Li, Maochen,Wang, Han,Tian, Lili,Pang, Zehan,Yang, Qingkun...&Fan, Huahao.(2022).COVID-19 vaccine development: milestones, lessons and prospects.SIGNAL TRANSDUCTION AND TARGETED THERAPY,7,(1)
MLA:
Li, Maochen,et al."COVID-19 vaccine development: milestones, lessons and prospects".SIGNAL TRANSDUCTION AND TARGETED THERAPY 7..1(2022)